NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 160 filers reported holding NEVRO CORP in Q1 2023. The put-call ratio across all filers is 0.53 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,365,645 | -24.9% | 331,199 | -0.6% | 0.00% | -50.0% |
| Q2 2023 | $8,470,884 | -30.3% | 333,237 | -0.9% | 0.00% | 0.0% |
| Q1 2023 | $12,153,847 | -8.2% | 336,206 | +0.5% | 0.00% | -33.3% |
| Q4 2022 | $13,242,517 | -10.3% | 334,407 | +5.6% | 0.00% | 0.0% |
| Q3 2022 | $14,760,000 | +5.4% | 316,741 | -0.9% | 0.00% | 0.0% |
| Q2 2022 | $14,009,000 | -41.1% | 319,605 | -2.8% | 0.00% | -25.0% |
| Q1 2022 | $23,770,000 | -14.5% | 328,645 | -4.2% | 0.00% | -20.0% |
| Q4 2021 | $27,802,000 | -33.6% | 342,928 | -4.8% | 0.01% | -28.6% |
| Q3 2021 | $41,900,000 | -30.3% | 360,031 | -0.8% | 0.01% | -36.4% |
| Q2 2021 | $60,151,000 | +11.1% | 362,816 | -6.5% | 0.01% | +10.0% |
| Q1 2021 | $54,157,000 | -30.2% | 388,230 | -13.4% | 0.01% | -33.3% |
| Q4 2020 | $77,642,000 | +23.1% | 448,540 | -0.9% | 0.02% | +7.1% |
| Q3 2020 | $63,065,000 | +13.1% | 452,728 | -3.0% | 0.01% | +7.7% |
| Q2 2020 | $55,745,000 | +38.8% | 466,601 | +16.1% | 0.01% | +8.3% |
| Q1 2020 | $40,168,000 | -11.4% | 401,765 | +4.1% | 0.01% | +20.0% |
| Q4 2019 | $45,350,000 | +32.7% | 385,832 | -3.0% | 0.01% | +25.0% |
| Q3 2019 | $34,184,000 | +38.3% | 397,620 | +4.3% | 0.01% | +33.3% |
| Q2 2019 | $24,724,000 | +9.2% | 381,354 | +5.3% | 0.01% | 0.0% |
| Q1 2019 | $22,637,000 | +56.8% | 362,140 | -2.4% | 0.01% | +50.0% |
| Q4 2018 | $14,433,000 | -32.4% | 371,136 | -0.9% | 0.00% | -20.0% |
| Q3 2018 | $21,341,000 | -27.0% | 374,405 | +2.3% | 0.01% | -28.6% |
| Q2 2018 | $29,221,000 | +3.1% | 365,960 | +11.9% | 0.01% | 0.0% |
| Q1 2018 | $28,338,000 | +26.4% | 326,961 | +0.7% | 0.01% | +16.7% |
| Q4 2017 | $22,415,000 | -26.4% | 324,667 | -3.1% | 0.01% | -25.0% |
| Q3 2017 | $30,463,000 | +26.0% | 335,198 | +3.2% | 0.01% | +14.3% |
| Q2 2017 | $24,185,000 | -8.9% | 324,930 | +14.7% | 0.01% | -12.5% |
| Q1 2017 | $26,543,000 | +31.0% | 283,283 | +1.6% | 0.01% | +33.3% |
| Q4 2016 | $20,258,000 | -35.7% | 278,806 | -7.6% | 0.01% | -40.0% |
| Q3 2016 | $31,505,000 | +47.0% | 301,801 | +3.9% | 0.01% | +42.9% |
| Q2 2016 | $21,426,000 | +92.6% | 290,482 | +44.4% | 0.01% | +75.0% |
| Q1 2016 | $11,123,000 | -12.3% | 201,188 | +7.1% | 0.00% | 0.0% |
| Q4 2015 | $12,677,000 | +42.2% | 187,780 | -2.3% | 0.00% | +33.3% |
| Q3 2015 | $8,915,000 | +61.0% | 192,185 | +86.5% | 0.00% | +50.0% |
| Q2 2015 | $5,538,000 | +22.5% | 103,029 | +9.2% | 0.00% | +100.0% |
| Q1 2015 | $4,522,000 | +48.2% | 94,345 | +19.6% | 0.00% | 0.0% |
| Q4 2014 | $3,051,000 | – | 78,893 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |